CymitQuimica logo

CAS 899796-83-9

:

Milatuzumab

Description:
Milatuzumab is a monoclonal antibody that targets the CD74 protein, which is often overexpressed in certain types of cancer, particularly B-cell malignancies. This therapeutic agent is designed to inhibit tumor growth and promote immune-mediated destruction of cancer cells. Milatuzumab is characterized by its specificity for CD74, which is involved in antigen presentation and is associated with the immune response. The antibody's mechanism of action includes inducing apoptosis in targeted cells and facilitating antibody-dependent cellular cytotoxicity (ADCC). It is typically administered in a clinical setting, often in combination with other therapies, to enhance its efficacy. As a biologic drug, Milatuzumab is produced through recombinant DNA technology, and its stability and efficacy are influenced by factors such as formulation, storage conditions, and administration route. Ongoing research continues to evaluate its potential in various therapeutic contexts, including its role in combination therapies for hematological cancers.
Formula:Unspecified
Synonyms:
  • hLL 1
  • Immunoglobulin G1, anti-(human class II antigen invariant chain) (human-mouse monoclonal hLL1 heavy chain), disulfide with human-mouse monoclonal hLL1 κ-chain, dimer
  • IMMU 115
  • Immunoglobulin G1, anti-(human CD74 antigen) (human-mouse monoclonal hLL1 heavy chain), disulfide with human-mouse monoclonal hLL1 κ-chain, dimer
  • Milatuzumab
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.